After Soaring 182% Is Time To Ring The Register In P3 Health?

P3 Health Partners stock chart

Key Points

  • After soaring 182% in May, a recent trendline break might signal a shift in momentum.
  • The company has experienced a significant increase in institutional inflow over a 12-month period.
  • Recent insider transactions, including purchases made by the CEO and CFO, give investors confidence.
  • 5 stocks we like better than P3 Health Partners

One of the best-performing stocks this month is a company you might have never heard of. Shares of P3 Health Partners NASDAQ: PIII are up 182% so far in May, but a recent trendline break and volume decrease could signal a character shift.

P3 Health Partners is a patient-centered and physician-led population health management company that provides superior care services in the United States. The company operates clinics and wellness centers throughout the Country and is based in Henderson, Nevada.

The breakout and move higher in shares if PIII started at the beginning of May when the company announced its first-quarter results. Were strong results the sole reason behind the significant increase in valuation, and can it be sustained? Or are other contributing factors at play?

First Quarter Results

On May 10th, P3 Health Partners announced their results for the first quarter. Capitated revenue increased 11% over the prior year to $298.7 million, and net loss improved 14%. First quarter medical margin increased 58% vs. the same period in the prior year.

CEO of P3, Dr. Sherif Abdou, said the following about the earnings report: “We are off to a strong start in 2023. As a result of the first quarter strength, we are increasing our adjusted EBITDA guidance today.”

Insider Trades and Institutional Ownership

Recent insider transactions will certainly give investors of P3 Health Partners a lot of confidence. In total, $7.31 million worth of insider buying occurred in April and May. While a major shareholder accounting for most insider buys, the company’s CEO and CFO also bought stock. The CEO purchased 108,225 shares at an average price of $2.63, and the CFO purchased 18,868 at an average price of $2.65. The recent purchases take the insider ownership of PIII  up to 23.6%.

The current institutional ownership in PIII is just over 51%. Over the last 12 months, the institutional inflow has rapidly increased, with $125.45 million in inflows. There were just $4.36 million in institutional outflows in the same period.

Significant Short Interest

As is typically the case with small-cap companies, the short interest will increase when a stock rises significantly in a short period. Short to medium-term traders might be looking for a pullback if they believe the stock is overbought. Of course, as the stock trades higher, short positions might be forced to cover, creating more demand, ultimately resulting in a short squeeze.

As of May 15th, the short interest was 20.6%, representing 3.3 million shares sold short. Typically, a short interest over 20% can be categorized as high. 

Is It Time To Sell?

While all the above developments and factors make for a bullish case, you cannot ignore the chart and price action of the stock.


Shares of PIII recently tested a significant area of resistance above $4 and failed to hold above, thereby confirming resistance. After failing to hold over resistance, and despite strength in the overall markets, the stock broke the uptrend support on Friday and fell 8.68%. 

The uptrend had been intact since the beginning of May. Such a move signals a change of character and momentum shifting from the upside to the downside.

Unless the stock can reclaim $4 - $4.50 and turn resistance into newfound support, further pullback and profit-taking will likely be the outcome.

Should you invest $1,000 in P3 Health Partners right now?

Before you consider P3 Health Partners, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and P3 Health Partners wasn't on the list.

While P3 Health Partners currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
P3 Health Partners (PIII)
1.3324 of 5 stars
$0.45-7.0%N/A-0.69Moderate Buy$4.75
Compare These Stocks  Add These Stocks to My Watchlist 

Ryan Hasson

About Ryan Hasson

  • Ry.has7@gmail.com

Contributing Author

Technical Analysis, Momentum Trading, Risk Management

Experience

Ryan Hasson has been a contributing writer for MarketBeat since 2023.

Areas of Expertise

Equity research and analysis, technical analysis and price action, market sentiment and underlying themes, risk management and trading psychology

Education

Bachelor of Commerce in Financial Management

Past Experience

Equities trader, Kershner Trading Group, business analysis consultant, SMB Capital

Zoom International: Business Analysis Consultant.


Featured Articles and Offers

Search Headlines: